BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1073 related articles for article (PubMed ID: 33651090)

  • 21. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
    von Stackelberg A; Locatelli F; Zugmaier G; Handgretinger R; Trippett TM; Rizzari C; Bader P; O'Brien MM; Brethon B; Bhojwani D; Schlegel PG; Borkhardt A; Rheingold SR; Cooper TM; Zwaan CM; Barnette P; Messina C; Michel G; DuBois SG; Hu K; Zhu M; Whitlock JA; Gore L
    J Clin Oncol; 2016 Dec; 34(36):4381-4389. PubMed ID: 27998223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of blinatumomab, a novel immunotherapy.
    Newman MJ; Benani DJ
    J Oncol Pharm Pract; 2016 Aug; 22(4):639-45. PubMed ID: 26607163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia.
    van der Sluis IM; de Lorenzo P; Kotecha RS; Attarbaschi A; Escherich G; Nysom K; Stary J; Ferster A; Brethon B; Locatelli F; Schrappe M; Scholte-van Houtem PE; Valsecchi MG; Pieters R
    N Engl J Med; 2023 Apr; 388(17):1572-1581. PubMed ID: 37099340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Lee S
    Cancer Med; 2019 Dec; 8(18):7650-7659. PubMed ID: 31691536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blinatumomab consolidation and maintenance therapy in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia.
    Rambaldi A; Huguet F; Zak P; Cannell P; Tran Q; Franklin J; Topp MS
    Blood Adv; 2020 Apr; 4(7):1518-1525. PubMed ID: 32289160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
    King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
    Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
    Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
    Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.
    Park JR; Kreissman SG; London WB; Naranjo A; Cohn SL; Hogarty MD; Tenney SC; Haas-Kogan D; Shaw PJ; Kraveka JM; Roberts SS; Geiger JD; Doski JJ; Voss SD; Maris JM; Grupp SA; Diller L
    JAMA; 2019 Aug; 322(8):746-755. PubMed ID: 31454045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.
    Halford Z; Coalter C; Gresham V; Brown T
    Ann Pharmacother; 2021 Oct; 55(10):1236-1253. PubMed ID: 33435716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pretransplant Blinatumomab Improves Outcomes in B Cell Acute Lymphoblastic Leukemia Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation.
    Sayyed A; Chen C; Gerbitz A; Kim DDH; Kumar R; Lam W; Law AD; Lipton JH; Michelis FV; Novitzky-Basso I; Viswabandya A; Mattsson J; Pasic I
    Transplant Cell Ther; 2024 May; 30(5):520.e1-520.e12. PubMed ID: 38462215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
    Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K
    Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.
    Jabbour E; Short NJ; Jain N; Haddad FG; Welch MA; Ravandi F; Kantarjian H
    J Hematol Oncol; 2023 Mar; 16(1):22. PubMed ID: 36927623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
    Ribera JM
    Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Use of blinatumomab in children acute lymphoblastic leukemia in the Grand Ouest interregion: A chance for all].
    Camuset M; Grain A; Lorton F; Minckes O; Jourdain A; Millot F; Pellier I; Gandemer V; Battisti FR
    Bull Cancer; 2019 Mar; 106(3):206-215. PubMed ID: 30638898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of relapse patterns in patients with acute lymphoblastic leukemia treated with blinatumomab.
    Lau KM; Saunders IM; Goodman AM
    J Oncol Pharm Pract; 2021 Jun; 27(4):821-826. PubMed ID: 32605497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
    Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
    J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insights from the Greek experience of the use of Blinatumomab in pediatric relapsed and refractory acute lymphoblastic leukemia patients.
    Ampatzidou M; Kattamis A; Baka M; Paterakis G; Anastasiou T; Tzanoudaki M; Kaisari A; Avgerinou G; Doganis D; Papadakis V; Kitra V; Polychronopoulou S
    Neoplasma; 2020 Nov; 67(6):1424-1430. PubMed ID: 32701357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies.
    Kantarjian HM; Stein AS; Bargou RC; Grande Garcia C; Larson RA; Stelljes M; Gökbuget N; Zugmaier G; Benjamin JE; Zhang A; Jia C; Topp MS
    Cancer; 2016 Jul; 122(14):2178-85. PubMed ID: 27143254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression.
    Jabbour E; Düll J; Yilmaz M; Khoury JD; Ravandi F; Jain N; Einsele H; Garcia-Manero G; Konopleva M; Short NJ; Thompson PA; Wierda W; Daver N; Cortes J; O'brien S; Kantarjian H; Topp MS
    Am J Hematol; 2018 Mar; 93(3):371-374. PubMed ID: 29178361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
    Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
    Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.